Laurent Levy

Laurent Levy (born 1971) is a French physical chemist, inventor, and pioneer of nanotechnology and nanomedicine. He is the co-founder of the global biotechnology company Nanobiotix, and has served as Chief Executive Officer (CEO) since its inception in March 2003.[1][2][3][4] He also authored more than 35 international scientific publications and has applied for several patents.[5]

Laurent Levy
Born1971
Montreuil, France
EducationPierre and Marie Curie University, now Paris-Sorbonne University (BS, MS)
SUNY Buffalo (PhD)
OccupationCEO of Nanobiotix

Early life and education

Laurent Levy was born on the outskirts of northern-east Paris, France, in Montreuil.

After high school, Laurent went on to study biology at Pierre and Marie Curie University (Paris VI). He changed his area of study to biophysics then to physics and chemistry after two years, graduating with his bachelor's degree in 1994. He then earned his MASTER (DEA) in physics of condensed matter from UPVI-ESPCI.[6]

Laurent attended Paris VI and the CEA for doctoral studies in physical chemistry, specializing in nanomaterials. His doctoral thesis centered on quantum confinement as it relates to magnetic semiconductors.[7]

Following the receipt of his doctorate, Levy completed a postdoctoral fellowship with Dr. Paras Prasad at the Institute for Lasers, Photonics, and Biophotonics at SUNY Buffalo in the United States.[8][9][10]

Work

In 2003, Levy founded Nanobiotix to create a medical treatment using the techniques he developed at SUNY Buffalo. Nanobiotix would build on his work to develop what is now known as NBTXR3, a first-in-class “radioenhancer” designed to significantly increase the efficacy of radiation therapy without increasing negative side effects associated with radiation. In 2011, Nanobiotix treated its first patient using NBTXR3. In 2018 the results of a phase III clinical trial established that this new type of product could work in humans. In 2019 the company received approval to sell NBTXR3 in Europe under the brand name Hensify® for the treatment of soft tissue sarcomas of the extremities and trunk wall.[11][12][13][14] In 2015 Levy joined the board of biotech startup Valbiotis, the first company to register a nutraceutical based on clinical findings. The company develops nutraceutical products for the prevention of diabetes in pre-diabetics. Levy helped take Valbiotis public in 2018.[15][16]

In 2019, Levy co-founded the biotechnology company Curadigm as a spin-off from Nanobiotix. Curadigm's lead technology is a nanoprimer that affects liver function, reducing its ability to filter out drugs, making drug delivery more efficacious.[17][18][19]

European nanomedicine advocacy

As Nanobiotix grew, Levy became increasingly frustrated at the struggles nanomedicine companies faced in gaining visibility and support in the European Union. To advocate for nanomedical development, Levy joined the European Technology Platform Nanomedicine (ETPN) in 2012 and was elected Vice President.[20][21][22] Levy is a founding member of the ETPN Translation Advisory Board, which has supported 109 European biotech entrepreneurs in launching their companies. Levy also helped to establish the ETPN's Nanomedicine Translation Hub, which advises SMEs, Startups, Academics and Inventors on how to bring their nanomedicine projects to the market.[23][24]

Awards and recognition
  • 2019 Prix Galien[25]
  • 2018
    • CPhI Pharma Award - Excellence in Pharma: CEO of the year Laurent Levy
    • CPhI Pharma Award - Pharma Company of the year : Nanobiotix
    • European Business Award 2018 : The award for Innovation
  • 2016 European Mediscience Award: Best technology Award
  • 2015 Prix de la relation actionnaires
  • 2013 University of Buffalo Young Entrepreneurs Prize : Laurent Levy[26]
  • 2006 Paris Bio Prize
  • 2003 Inventor of the year: Niagara frontier intellectual property law association

Patents

Publications
  • Levy, Laurent; Sahoo, Yudhisthira; Kim, Kyoung-Soo; Bergey, Earl J.; Prasad, Paras N. (2002). "Nanochemistry: Synthesis and Characterization of Multifunctional Nanoclinics for Biological Applications". Chemistry of Materials. American Chemical Society (ACS). 14 (9): 3715–3721. doi:10.1021/cm0203013. ISSN 0897-4756.CS1 maint: ref=harv (link)
  • Maggiorella, Laurence; Barouch, Gilles; Devaux, Corinne; Pottier, Agnès; Deutsch, Eric; Bourhis, Jean; Borghi, Elsa; Levy, Laurent (2012). "Nanoscale radiotherapy with hafnium oxide nanoparticles". Future Oncology. Future Medicine Ltd. 8 (9): 1167–1181. doi:10.2217/fon.12.96. ISSN 1479-6694. PMID 23030491.CS1 maint: ref=harv (link)
  • Bergey, Earl J.; Levy, Laurent; Wang, Xiaopeng; Krebs, Linda J.; Lal, Manjari; Kim, Kyoung-Soo; Pakatchi, Shadi; Liebow, Charles; Prasad, Paras N. (2002). "DC Magnetic Field Induced Magnetocytolysis of Cancer Cells Targeted by LH-RH Magnetic Nanoparticles in vitro". Biomedical Microdevices. Springer Science and Business Media LLC. 4 (4): 293–299. doi:10.1023/a:1020906307053. ISSN 1387-2176.CS1 maint: ref=harv (link)

References
  1. "Laurent Levy". The Pharma Letter. Retrieved 2020-03-05."Interview: Laurent Levy – CEO, Nanobiotix, France". PharmaBoardroom. 2017-06-13. Retrieved 2020-03-05.
  2. "Interview with Laurent Levy, CEO of Nanobiotix - BioFIT 2020". BioFIT 2020. 2016-11-08. Retrieved 2020-03-05.
  3. "Dr. Laurent Levy, CEO of Nanobiotix, Receives UB Entrepreneurship Award". Applied Sciences from Technology Networks. 2013-04-04. Retrieved 2020-03-05.
  4. "The management". Nanobiotix. 2019-02-28. Retrieved 2020-03-05.
  5. "Levy, Laurent". The Wall Street Transcript. 2020-03-20. Retrieved 2020-06-17.
  6. Levy, L.; Hochepied, J. F.; Pileni, M. P. (1996). "Control of the Size and Composition of Three Dimensionally Diluted Magnetic Semiconductor Clusters". The Journal of Physical Chemistry. American Chemical Society (ACS). 100 (47): 18322–18326. doi:10.1021/jp960824w. ISSN 0022-3654.CS1 maint: ref=harv (link)
  7. Levy, L.; Feltin, N.; Ingert, D.; Pileni, M. P. (1997). "Three Dimensionally Diluted Magnetic Semiconductor Clusters Cd1-yMnyS with a Range of Sizes and Compositions: Dependence of Spectroscopic Properties on the Synthesis Mode". The Journal of Physical Chemistry B. American Chemical Society (ACS). 101 (45): 9153–9160. doi:10.1021/jp970978r. ISSN 1520-6106.CS1 maint: ref=harv (link)
  8. "The management". Nanobiotix. 2019-02-28. Retrieved 2020-03-06.
  9. "UB spinoff Nanobiotix looks to bring cancer treatment to market". University at Buffalo. 2014-05-23. Retrieved 2020-03-06.
  10. Editorial, Reuters (2020-03-05). "Officer Profile - Quotes". IN. Retrieved 2020-03-06.
  11. Bonvalot, Sylvie; Rutkowski, Piotr L; Thariat, Juliette; Carrère, Sébastien; Ducassou, Anne; Sunyach, Marie-Pierre; Agoston, Peter; Hong, Angela; Mervoyer, Augustin; Rastrelli, Marco; Moreno, Victor; Li, Rubi K; Tiangco, Béatrice; Herraez, Antonio Casado; Gronchi, Alessandro; Mangel, László; Sy-Ortin, Teresa; Hohenberger, Peter; Baère, Thierry de; Cesne, Axel Le; Helfre, Sylvie; Saada-Bouzid, Esma; Borkowska, Aneta; Anghel, Rodica; Co, Ann; Gebhart, Michael; Kantor, Guy; Montero, Angel; Loong, Herbert H; Vergés, Ramona; Lapeire, Lore; Dema, Sorin; Kacso, Gabriel; Austen, Lyn; Moureau-Zabotto, Laurence; Servois, Vincent; Wardelmann, Eva; Terrier, Philippe; Lazar, Alexander J; Bovée, Judith V M G; Péchoux, Cécile Le; Papai, Zsusanna (2019-08-01). "NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial". The Lancet Oncology. 20 (8): 1148–1159. doi:10.1016/S1470-2045(19)30326-2. ISSN 1470-2045. PMID 31296491. Retrieved 2020-03-05.
  12. Swift, Diana (2019-07-16). "Novel Radioenhancer Boosts RT Response in Sarcoma". MedPage Today. Retrieved 2020-03-05.
  13. Bonvalot, Sylvie; Le Pechoux, Cécile; De Baere, Thierry; Kantor, Guy; Buy, Xavier; Stoeckle, Eberhard; Terrier, Philippe; Sargos, Paul; Coindre, Jean Michel; Lassau, Nathalie; Ait Sarkouh, Rafik; Dimitriu, Mikaela; Borghi, Elsa; Levy, Laurent; Deutsch, Eric; Soria, Jean-Charles (2016-12-22). "First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas". Clinical Cancer Research. 23 (4): 908–917. doi:10.1158/1078-0432.CCR-16-1297. PMID 27998887.
  14. Cynthia E. Keen. "Potential benefits of adding radioenhancer nanoparticles to RT treatment for soft-tissue sarcoma". Applied Radiation Oncology. Retrieved 2020-03-05.
  15. "Research & Development Company". Valbiotis. 2018-07-31. Retrieved 2020-03-05.
  16. "VALBIOTIS Announces Positive Results From the Phase IIA Clinical Study of VALEDIA®, Now the First Product Proven Effective in People With Prediabetes". BioSpace. 2019-07-03. Retrieved 2020-03-05.
  17. "Together to Reshape Healthcare Full Version". Curadigm. 2019-05-17. Retrieved 2020-03-05.
  18. "New Nanobiotix subsidiary to use 'nanoprimer' tech". The Pharma Letter. Retrieved 2020-03-05.
  19. Pottier, Agnès; Levy, Laurent; Bergere, Maxime; Mpambani, Francis; Berjaud, Céline; Paolini, Marion; Poul, Laurence; Meyre, Marie-Edith; Germain, Matthieu (19 March 2018). "Priming the body to receive the therapeutic agent to redefine treatment benefit/risk profile - Scientific Reports". Scientific Reports. 8 (1): 4797. doi:10.1038/s41598-018-23140-9. PMC 5859131. PMID 29556068.
  20. Lévy, Laurent (2014). "Europe as leaders in nanomedicine: let's go for it!". Nanomedicine. Future Medicine Ltd. 9 (4): 389–391. doi:10.2217/nnm.14.14. ISSN 1743-5889. PMID 24787438.CS1 maint: ref=harv (link)
  21. Eaton, Michael A.W. (June 2012). "Improving the translation in Europe of nanomedicines (a.k.a. drug delivery) from academia to industry". Journal of Controlled Release. 164 (3): 370–371. doi:10.1016/j.jconrel.2012.06.016. PMID 22721816. Retrieved 5 March 2020.
  22. Eaton, Mike (March 2018). "Improving Innovation in Nano-Healthcare Funding". Precision Nanomedicine. 1. doi:10.29016/180108.1.
  23. "HealthtechTAB". HealthtechTAB. 2019-10-11. Retrieved 2020-03-05.
  24. "ETPN". The Nanomedicine Translation Hub. Retrieved 2020-03-05.
  25. "Nanotech company Nanobiotix earns Prix Galien Award for innovation". Applied Radiation Oncology. Dec 17, 2019. Retrieved 5 March 2020.
  26. "Dr. Laurent Levy, CEO of Nanobiotix, Receives UB Entrepreneurship Award". Applied Sciences from Technology Networks. 2013-04-04. Retrieved 2020-03-05.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.